- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline.
-
- HANADA Mitsuharu
- Discovery Research Laboratories II, Sumitomo Pharmaceuticals Co., Ltd.
-
- NOGUCHI Toshihiro
- Discovery Research Laboratories II, Sumitomo Pharmaceuticals Co., Ltd.
-
- MURAYAMA Takao
- Marketing & Promotion Planning, Sumitomo Pharmaceuticals Co., Ltd.
Bibliographic Information
- Other Title
-
- 全合成アントラサイクリン系抗癌薬塩酸アムルビシン(カルセド)の抗腫よう作用
- 新薬紹介総説 全合成アントラサイクリン系抗癌薬塩酸アムルビシン(カルセド)の抗腫瘍作用
- シンヤク ショウカイ ソウセツ ゼンゴウセイ アントラサイクリンケイ コウガンヤク エンサン アムルビシン カルセド ノ コウシュヨウ サヨウ
Search this article
Description
Amrubicin is a completely synthetic anthracycline derivative. In contrast, however, the anthracyclines used clinically thus far have been produced by fermentation or semisynthesis. Amrubicin is structurally distinguishable from other anthracyclines by the amino group at the 9-position and its unique sugar moiety. Amrubicinol, the C-13 hydroxy- metabolite of amrubicin, is associated with a 5 to 200 times greater cytotoxicity than amrubicin. Amrubicin exhibited superior in vivo antitumor activity to doxorubicin in the human tumor xenograft model. Using this model, the level of amrubicinol (active metabolite) was shown to be higher than that of doxorubicin in tumor tissues, but lower in normal tissues. These results suggest potent therapeutic activity for amrubicin because of the selective distribution of its highly active metabolite, amrubicinol, in tumors. These anti-tumor effects of amrubicin are considered to be induced by DNA topoisomeraseII inhibition. In clinical studies, amrubicin has demonstrated potent single agent activity as compared to a standard regimen in untreated patients with extensive small cell lung cancer. Its major toxicity was myelosuppression (especially neutropenia).<br>
Journal
-
- Folia Pharmacologica Japonica
-
Folia Pharmacologica Japonica 122 (2), 141-150, 2003
The Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679248984320
-
- NII Article ID
- 130000085958
-
- NII Book ID
- AN00198335
-
- COI
- 1:STN:280:DC%2BD3szlvVKmsw%3D%3D
-
- ISSN
- 13478397
- 00155691
-
- NDL BIB ID
- 6655828
-
- PubMed
- 12890900
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed